Immediate Introduction of Everolimus Does Not Affect Wound Healing and Delayed Graft Function in Kidney Transplant Recipients: 3-Months Results from NEVERWOUND Study

The NEVERWOUND study was designed to evaluate the impact of immediate vs. delayed introduction of everolimus on wound healing complications (WHC) and delayed graft function in de novo kidney transplant recipiemts during the first 3 months post-Tx. We enrolled 383 single kidney Tx recipients to: immediate EVR (0.75 mg twice daily), within 48 hours afterr graft reperfusion along with low dose CsA with a bridge of enteric coated mycophenol,ate sodium and CSA. All patient received induction therapy and steroids as per local clinical practice. Primary endpoint is the proportion of patients without WHC realated to initial transplant surgery (Fluid collections, wound dehiscence, wound infections, incisional hernia). Secondary endpoints are the rate of treatment failure (composite endpoint: biopsy-proven acute rejection, graft loss death). The immediate intriduction of EVR post Tx did not increase the risk of WHC snd showed DGF incidence and duration comparable to delayed introduction comparable rates were observed for the two treatment groups (p=NS). Treatment 5.5 days of dialysis in iEVR and dEVR groups respectively (p=0.21). No differences 